Evidence map›Paper›PMID 36255239›Full record

Trial reportmBio2022

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.

Andrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, Eleftherios Mylonakis, Shazia Ali, Jingning Mei, Rafia Bhore, Adnan Mahmood, Gregory P Geba, Paula Dakin and 5 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Andrea T Hooper *Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.ORCID 0000-0003-1131-1229
Selin Somersan-Karakaya *Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Shane E McCarthyRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Eleftherios MylonakisBrown University, Providence, Rhode Island, USA.ORCID 0000-0002-4624-0777
Shazia AliRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Jingning MeiRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Rafia BhoreRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Adnan MahmoodRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Gregory P GebaRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Paula DakinRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
David M WeinreichRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
George D YancopoulosRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Gary A HermanRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Jennifer D HamiltonRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
COVID-19 Phase 2/3 Hospitalized Trial Team
Regeneron (United States) · USBrown University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a

Indexed as

COVID-19SARS-CoV-2Antibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, ViralDrug CombinationsHumansOxygenViral LoadAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntibodies, Viralcasirivimab and imdevimab drug combinationDrug CombinationsOxygenanti-SARS-CoV-2 serostatuscasirivimab and imdevimabCOVID-19hospitalizedmonoclonal antibodiesneutralizing antibodies

Identifiers

PMID36255239
PMCPMC9765482
OpenAlexW4306728772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.